Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some positive stock-specific news.
Among the regulatory decisions for the week, the Food and Drug Administration gave the green light to argenx SE’s efgartigimod for the treatment of generalized myasthenia gravis.
